FREIER SUSAN M.,MONIA BRETT P.,ZHANG HONG,ZHAO CHENGUANG,CROSBY JEFFREY R.,SIWKOWSKI ANDREW M.
申请号：
NZ60360309
公开号：
NZ603603A
申请日:
2009.10.15
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Disclosed is a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, targeted to a Factor 11 nucleic acid, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary to an equal length portion of SEQ ID NO: 1, and wherein the oligonucleotide is capable of inhibiting Factor 11 expression, and wherein the compound is not a compound comprising a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 1275 to 1318 of SEQ ID NO: 1 wherein the sequences are as disclosed in the specification. Also disclosed is the use of a Factor 11 inhibitor in combination with anti-platelet therapy for treating thromboembolic complications.
